Abstract: A method for inhibiting inflammatory in a subject is provided, comprising: administering a pharmaceutical composition comprising an effective amount of 9,11-secosteroids.

Abstract: A sole data collection device and a sole data collection method are disclosed. The sole data collection device includes an image capture module, a temperature detection module and a monofilament testing module. The sole data collection device is used for collecting the sole data of a user, and the sole data is transmitted to a cloud server. The sole data collection device and the sole data collection method are not only convenient for a user to collect sole data at home at any time, but also allow the user's caregiver and/or relevant medical care personnel to extract the sole data from the cloud server to screen the user's plantar condition, so as to solve the problem that it is time-consuming and costly to go to a medical institution for relevant examinations.

Abstract: An Oncidium plant extract and methods for treating diabetes mellitus, liver protection and preventing acute respiratory distress syndrome thereof are provided, the steps for extracting the Oncidium plant extract include taking an Oncidium plant sample, drying and grinding the sample to obtain a ground Oncidium plant sample, and then extracting the ground Oncidium plant sample in a solvent by an accelerated solvent extraction or an ultrasonic extraction to obtain an Oncidium plant extract.

Abstract: Disclosed herein is related to a method for extending lifespan and/or delaying aging in a subject; the method comprises administering to the subject with an effective amount of (24S)-3?-hydroxy-5?-stigmastan-6-one, wherein the delaying aging comprises increasing vitality, muscle strength or motor coordination, insulin sensitivity, or basal metabolic rate; and/or reducing muscle weakness, loss of balance, hair graying, kyphosis, or hyperglycemia. Also encompassed in the present disclosure are methods for promoting weight loss or treating type 2 diabetes mellitus in a subject, in which the methods comprise administering to the subject an effective amount of (24S)-3?-hydroxy-5?-stigmastan-6-one.

Abstract: The present invention relates to a gallium nitride transimpedance amplifier, as an essential electronic circuit in the proton beam therapy. Because gallium nitride is more tolerant to the secondary radiation generated during the proton beam therapy, it has high reliability and increases the reliability of the overall system.

Abstract: Disclosed herein is a method for alleviating dry eye syndrome using a composition containing a polylysine nanoparticle. The polylysine nanoparticle is produced by subjecting lysine hydrochloride to a pyrolysis treatment at a temperature ranging from 240° C. to 280° C.

Abstract: Disclosed herein is a method for determining whether a subject has or is at risk of developing colorectal cancer with an ex vivo biological sample isolated from the subject. The method comprises: determining the levels of at least two target proteins with the aid of mass spectrometry, in which the at least two target proteins are selected from the group consisting of ADAM10, CD59, and TSPAN9; and assessing whether the subject has or is at risk of developing the colorectal cancer based on the levels of the at least two target proteins. The present method may serve as a potential means for diagnosing and predicting the incidence of colorectal cancer, and the subject in need thereof could receive a suitable therapeutic regimen in time in accordance with the diagnostic results produced by the present method.

Abstract: A method for performing contactless ODEP for separation of CTCs is provided with the steps of obtaining patients' blood with rare cell suspected CTCs; adding at least one fluorescent antibody binding to CTCs into the blood; staining the blood; injecting the stained blood with fluorescent dye into an ODEP device and then performing fluorescent image identification; trapping the CTCs with at least one fluorescent antibody in the ODEP device by creating an image pattern and then generating an ODEP force; Separating the trapped CTCs from other non-CTCs cells; absorbing the trapped CTCs; and obtaining a high purity of CTCs. An apparatus for performing contactless ODEP for separation of CTCs is also provided.

Abstract: A method for promoting chronic wound healing is provided, including administering an effective amount of Bletilla formosana (Hayata) Schltr. extract to a subject in need thereof, wherein the effective amount of Bletilla formosana (Hayata) Schltr. extract is 0.01 mg/kg-body weight to 100 mg/kg-body weight, and wherein the chronic wound including diabetic wound and Diabetic Foot Ulcer.

Abstract: Disclosed herein is related to a method for treating a symptom associated with senescence in a subject by administering to the subject with an effective amount of corylin and/or neobavaisoflavone, wherein the symptom associated with senescence is loss of muscle strength, muscle weakness, loss of motor coordination, loss of balance, skin wrinkle, or a poor blood biochemical parameter.

Abstract: A method for predicting clinical severity of a neurological disorder includes steps of: a) identifying, according to a magnetic resonance imaging (MRI) image of a brain, brain image regions each of which contains a respective portion of diffusion index values of a diffusion index, which results from image processing performed on the MRI image; b) for one of the brain image regions, calculating a characteristic parameter based on the respective portion of the diffusion index values; and c) calculating a severity score that represents the clinical severity of the neurological disorder of the brain based on the characteristic parameter of the one of the brain image regions via a prediction model associated with the neurological disorder.

Abstract: A method for inhibiting infection of SARS-CoV-2 in a subject is provided, including administering to the subject a compound, wherein the compound comprises Aromoline, Obamegine, Berbamine or Bersavine.

Abstract: Disclosed herein is a method for alleviating dry eye syndrome using a composition containing a polylysine nanoparticle. The polylysine nanoparticle is produced by subjecting lysine hydrochloride to a pyrolysis treatment at a temperature ranging from 240° C. to 280° C.

Abstract: A method for inhibiting infection of SARS-CoV-2 in a subject is provided, comprising administering an effective amount of plant extract, wherein the plant extract comprises an alcohol extract of the herbal of Menispermaceae, wherein the herbal of Menispermaceae is Stephania cepharantha or Stephania tetrandra.

Abstract: Disclosed herein is a method for inhibiting virus infection, including administering to a subject in need thereof an effective amount of a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting viral replication, including contacting a virus with a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is a method for identifying and treating a Streptococcus pyogenes (group A Streptococcus, GAS) infection in a subject. The method mainly includes determining the presence of endopeptidase O (PepO) protein in the biological sample; and administering an effective amount of an anti-infective agent to the subject to ameliorate symptoms associated with the GAS infection if the PepO protein is present in the biological sample.

Abstract: Disclosed herein is a method of treating diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils. The method includes administering to a subject in need thereof an effective amount of 3,3?-dihydroxy-2?,6?-bis(p-hydroxybenzyl)-5-methoxybibenzyl (or bletinib), a salt, a solvate or an ester thereof.

Abstract: A center of pressure (CoP) based control system includes a sensing device and an electronic device connected to the sensing device. The sensing device includes sensors each of which continuously measures force exerted thereon by a subject and generates a sense signal based on a result of the measurement. The electronic device is connected to the sensing device, and receives the sense signals from the respective sensors, generates CoP data associated with a CoP trajectory based on the sense signals, determines whether a turning point exists in the CoP trajectory, generates an indication signal based on a result of the determination, and generates a control signal based on a direction of one of displacements of the CoP.

Abstract: A method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying microorganisms includes collecting m/z data of microorganisms having same features from MALDI-TOF MS; classifying the microorganisms; classifying the collected set of m/z data as a plurality of subsets; creating modified subsets by applying KDE to the subsets; creating first characteristic MS profiles based on the modified subsets; summarizing into a second characteristic MS profile; repeating above six steps to create second characteristic MS profiles; creating a training set comprising first matched vectors; training a machine learning system using the training set to establish a feature classification model; using MALDI-TOF MS to analyze microorganisms having unknown features; comparing m/z of MALDI-TOF MS spectrum of the microorganisms having unknown features with second characteristic MS profiles to obtain second matched vectors; using the feature classification model analyzing the second m

Abstract: A method for determining a human subject's risk of developing acute kidney injury (AKI) from acute myocardial infarction (AMI) includes: obtaining a blood sample; determining at least two miRNA expression levels therein, which are selected from miR-23a-3p, miR-24-3p, and miR-145-5p expression levels; calculating probability of developing AKI from AMI based on the at least two miRNA expression levels and a logistic regression model; comparing the probability with a predetermined standard; and determining that the human subject is at the risk of developing AKI when the probability is higher than the predetermined standard. A composition may be administered to the human subject for inhibiting development of AKI, if any.